Abstract: An example method includes: delivering one or more electrical stimulation pulses to one or more nerves of a patient via one or more inserted electrodes on a lead or formed on an evaluation needle and prior to implantation of an implantable medical device, the one or more nerves being associated with stimulation therapy; sensing an evoked signal generated by one or more signal sources in response to delivery of the one or more electrical stimulation pulses; determining, based at least in part on the evoked signal, a therapy response group of a plurality of therapy response groups for the patient, wherein the therapy response group indicates whether implantation of the implantable medical device is recommended; and outputting information indicative of the determined therapy response group.

Abstract: Described herein are peptide analogs of glucagon-like peptide 1 (GLP-1) that retain agonist activity, but are more resistant to proteolytic degradation than native GLP-1. In the analogs, at least one ?-amino acid found in the native GLP-1 is replaced with a ?-amino acid residue, which may or may not be cyclically constrained. Pharmaceutical compositions containing the analogs are described, as are methods to treat diabetes, and methods to make proteolytically resistant GLP-1 analogs.

Abstract: Described is a method of fabricating biologically active, unnatural polypeptides. The method includes the steps of selecting a biologically active polypeptide or biologically active fragment thereof having an amino acid sequence comprising ?-amino acid residues, and fabricating a synthetic polypeptide that has an amino acid sequence that corresponds to the sequence of the biologically active polypeptide, but wherein about 14% to about 50% of the ?-amino acid residues found in the biologically active polypeptide or fragment of step (a) are replaced with ?-amino acid residues, and the ?-amino acid residues are distributed in a repeating pattern.

Abstract: Described herein are peptide analogs of glucagon-like peptide 1 (GLP-1) that retain agonist activity, but are more resistant to proteolytic degradation than native GLP-1. In the analogs, at least one ?-amino acid found in the native GLP-1 is replaced with a ?-amino acid residue, which may or may not be cyclically constrained. Pharmaceutical compositions containing the analogs are described, as are methods to treat diabetes, and methods to make proteolytically resistant GLP-1 analogs.

Abstract: Described herein are peptide analogs of glucagon-like peptide 1 (GLP-1) that retain agonist activity, but are more resistant to proteolytic degradation than native GLP-1. In the analogs, at least one ?-amino acid found in the native GLP-1 is replaced with a ?-amino acid residue, which may or may not be cyclically constrained. Pharmaceutical compositions containing the analogs are described, as are methods to treat diabetes, and methods to make proteolytically resistant GLP-1 analogs.

Abstract: Described is a method of fabricating biologically active, unnatural polypeptides. The method includes the steps of selecting a biologically active polypeptide or biologically active fragment thereof having an amino acid sequence comprising ?-amino acid residues, and fabricating a synthetic polypeptide that has an amino acid sequence that corresponds to the sequence of the biologically active polypeptide, but wherein about 14% to about 50% of the ?-amino acid residues found in the biologically active polypeptide or fragment of step (a) are replaced with ?-amino acid residues, and the ?-amino acid residues are distributed in a repeating pattern.

Abstract: Described herein are peptide analogs of glucagon-like peptide 1 (GLP-1) that retain agonist activity, but are more resistant to proteolytic degradation than native GLP-1. In the analogs, at least one ?-amino acid found in the native GLP-1 is replaced with a ?-amino acid residue, which may or may not be cyclically constrained. Pharmaceutical compositions containing the analogs are described, as are methods to treat diabetes, and methods to make proteolytically resistant GLP-1 analogs.

Abstract: Described is a method of fabricating biologically active, unnatural polypeptides. The method includes the steps of selecting a biologically active polypeptide or biologically active fragment thereof having an amino acid sequence comprising ?-amino acid residues, and fabricating a synthetic polypeptide that has an amino acid sequence that corresponds to the sequence of the biologically active polypeptide, but wherein about 14% to about 50% of the ?-amino acid residues found in the biologically active polypeptide or fragment of step (a) are replaced with ?-amino acid residues, and the ?-amino acid residues are distributed in a repeating pattern.

Abstract: Described is a method of fabricating biologically active, unnatural polypeptides. The method includes the steps of selecting a biologically active polypeptide or biologically active fragment thereof having an amino acid sequence comprising ?-amino acid residues, and fabricating a synthetic polypeptide that has an amino acid sequence that corresponds to the sequence of the biologically active polypeptide, but wherein about 14% to about 50% of the ?-amino acid residues found in the biologically active polypeptide or fragment of step (a) are replaced with ?-amino acid residues, and the ?-amino acid residues are distributed in a repeating pattern.

Abstract: Described is a method of fabricating biologically active, unnatural polypeptides. The method includes the steps of selecting a biologically active polypeptide or biologically active fragment thereof having an amino acid sequence comprising ?-amino acid residues, and fabricating a synthetic polypeptide that has an amino acid sequence that corresponds to the sequence of the biologically active polypeptide, but wherein about 14% to about 50% of the ?-amino acid residues found in the biologically active polypeptide or fragment of step (a) are replaced with ?-amino acid residues, and the ?-amino acid residues are distributed in a repeating pattern.

Abstract: An improved security checkpoint separates certain individuals into a secure, enclosed wanding station for additional security screening. The wanding station may be constructed using glass (or other strong, visually transparent substance) and metallic (such as aluminum or steel) posts so that people may be securely enclosed in the wanding station but still have a direct line of sight to personal items being screened at another location. The size of the wanding station may vary according to the needs of the checkpoint but preferably has room to screen three people simultaneously. The wanding station may include an entry area in which people form a queue, optimally of six people, for entering the wanding station. Two or more personal and item screening areas may share a wanding station to form a double lane module. The security module is configured so that most people pass straight through the checkpoint, and people leaving the wanding station can easily obtain their items without delaying others.

Abstract: An improved security checkpoint separates certain individuals into a secure, enclosed wanding station for additional security screening. The wanding station may be constructed using glass (or other strong, visually transparent substance) and metallic (such as aluminum or steel) posts so that people may be securely enclosed in the wanding station but still have a direct line of sight to personal items being screened at another location. The size of the wanding station may vary according to the needs of the checkpoint but preferably has room to screen three people simultaneously. The wanding station may include an entry area in which people form a queue, optimally of six people, for entering the wanding station. Two or more personal and item screening areas may share a wanding station to form a double lane module. The security module is configured so that most people pass straight through the checkpoint, and people leaving the wanding station can easily obtain their items without delaying others.

Abstract: The present invention relates to a method and an apparatus for enhancing the optical image of information-containing symbols captured off highly reflective surfaces using a conventional optical touch camera. The method involves positioning the imaging assembly of the touch camera atop an information-containing coded symbol located on a component surface, positioning a diffuser element between the coded symbol and the imaging assembly, and moving the diffuser element into juxtaposition with the coded symbol before imaging the coded element.

Abstract: The present invention relates to a method and an apparatus for enhancing the optical image of information-containing symbols captured off reflective surfaces/using a conventional optical scanning camera. The method involves positioning the imaging assembly of the camera atop an information-containing coded symbol located on a component surface, where the imaging assembly includes a diffuser element and LED lighting array for illuminating the symbol, illuminating the surface and the symbol, and moving the diffuser element to a location between the coded symbol and the camera lens such that only light returning directly from the symbol is able to pass through the voided region of the diffuser element, before imaging the coded element.